Ozempic side effects and stopping GLP-1s: what's real

What did @just_laurie_angel_mom actually say?

She says semaglutide (which she calls "Mozambic" and Ozempic interchangeably) caused a cascade of serious symptoms while she was on it, that stopping it triggered thyroid dysfunction requiring high-dose levothyroxine, and that her blood glucose is now severely uncontrolled. She's asking whether anyone else has experienced a similar collapse after discontinuation.

Specifically, she reported blurred vision, cold sweats, confusion, difficulty swallowing, dizziness, rapid heartbeat, severe headaches, nausea, chest tightness, and trouble breathing while on the drug. She then says her husband was hospitalized with pancreatitis "likely" linked to Ozempic, which prompted her to connect her own symptoms to the medication. Since stopping, the cardiac and respiratory symptoms resolved, but she now has uncontrolled diabetes with readings of 18-22 mmol/L (roughly 324-396 mg/dL in US units) and a thyroid that is, in her words, "totally screwed up."

Does the science back this up?

Some of it does, some of it doesn't, and some of it genuinely cannot be answered with current evidence. The pancreatitis connection is the most documented. The thyroid and post-discontinuation blood sugar claims are where things get complicated.

Pancreatitis is listed as a serious warning in semaglutide's prescribing information. A 2022 pharmacovigilance analysis by Bezin et al. in Diabetes Care found elevated pancreatitis risk signals across GLP-1 receptor agonists, though absolute risk remains low. The cardiac symptoms she describes (palpitations, chest tightness, trouble breathing) are not classic semaglutide effects and more likely reflect anxiety, dehydration, or an unrelated cardiac issue, though her clinicians apparently couldn't explain them either. That's worth noting.

The thyroid claim is the most scientifically contested part of her story. In rodent studies, semaglutide activates GLP-1 receptors on C-cells in the thyroid, raising concerns about medullary thyroid carcinoma. That's why it carries a black box warning. But there is no established mechanism by which stopping semaglutide would cause hypothyroidism or require a sudden increase in levothyroxine dosing. It's possible her thyroid dysfunction is coincidental and unmasked by the stress of illness, not caused by the drug or its discontinuation.

What did they get wrong (or right)?

She got the pancreatitis warning right. That's a real, documented risk that appears in the drug's label and is supported by post-market surveillance data. Credit where it's due.

The claim that Ozempic "screwed up" her thyroid after stopping is more problematic. She's connecting two events in time and assuming causation. Thyroid dysfunction is extremely common in the general population, particularly in women, and nothing in the published literature supports a hypothesis that semaglutide discontinuation triggers hypothyroidism. It is genuinely possible her thyroid condition was developing independently and is only now being diagnosed.

Her blood sugar deterioration after stopping is actually expected and not mysterious. Semaglutide improves glycemic control through multiple mechanisms. When you remove it, blood glucose rises, sometimes sharply, in people with type 2 diabetes. A 2022 trial by Davies et al. in The Lancet confirmed significant glycemic rebound after GLP-1 agonist withdrawal. Her numbers (18-22 mmol/L) are dangerously high but not pharmacologically surprising given she lost a major glucose-lowering agent.

The list of symptoms she experienced on Ozempic, particularly "difficulty swallowing" and choking, is worth flagging. Gastroparesis-related symptoms have been increasingly reported with semaglutide. A 2023 study by Sodhi et al. in JAMA found elevated risks of gastroparesis and bowel obstruction in GLP-1 users. Dysphagia specifically is less documented but has appeared in case reports.

What should you actually know?

If you're on a GLP-1 agonist and experiencing chest tightness, severe abdominal pain, or persistent vomiting, those are reasons to call your doctor the same day, not reasons to diagnose yourself via TikTok comments.

The practical points here are real: GLP-1 agonists carry genuine risks that are sometimes underplayed in the weight loss conversation. Pancreatitis is rare but documented. Gastroparesis symptoms are increasingly being reported. Stopping semaglutide without a replacement plan will predictably cause blood sugar to spike in people with type 2 diabetes. None of that is controversial.

What's less defensible is the narrative that Ozempic is systematically destroying thyroids and causing multi-organ failure post-discontinuation. That's not supported by the current evidence. Her experience is real and her suffering is clearly real. But individual cases, even serious ones, are not the same as established drug effects. The thyroid dysfunction, the iron deficiency, and the dehydration each deserve separate clinical investigation rather than being bundled into a single Ozempic origin story.

• Anyone experiencing pancreatitis symptoms (severe upper abdominal pain radiating to the back, vomiting) while on a GLP-1 agonist should seek emergency care immediately.
• Post-discontinuation hyperglycemia is expected and requires a transition plan from your prescriber, not just stopping the drug.
• The thyroid black box warning on semaglutide relates to C-cell tumors observed in rodents, not hypothyroidism in humans.